UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

Annals of oncology, 2016-10, Vol.27 (10), p.1855-1860

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

Annals of oncology, 2013-01, Vol.24 (1), p.252-257

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

Clinical cancer research, 2007-10, Vol.13 (19), p.5841-5846

2007

Link zum Volltext

Verfügbarkeit prüfen

PP 66 Utility of VEGF and IL-6 as biomarkers for response to PTC299, a novel antiangiogenic

European journal of cancer (1990), 2011, Vol.47, p.S15-S15

2011

Link zum Volltext

Verfügbarkeit prüfen

9330 POSTER Memorial Sloan-Kettering Cancer Center (MSKCC) Single-Institutional Vulvovaginal Mucosal Melanoma (WMM) Experience From 1995-2010

European journal of cancer (1990), 2011, Vol.47, p.S661-S661

2011

Link zum Volltext

Verfügbarkeit prüfen

1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma

Annals of oncology, 2023-10, Vol.34, p.S1039-S1039

2023

Link zum Volltext

Verfügbarkeit prüfen

1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma

Annals of oncology, 2023-10, Vol.34, p.S1032-S1033

2023

Link zum Volltext

Verfügbarkeit prüfen

Development of cell-cycle inhibitors for cancer therapy

Current oncology (Toronto), 2009-03, Vol.16 (2), p.36-43

2009

Link zum Volltext

Verfügbarkeit prüfen

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

Annals of oncology, 2012-06, Vol.23 (6), p.1601-1607

2012

Link zum Volltext

Verfügbarkeit prüfen

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

European journal of cancer (1990), 2020-10, Vol.138, p.S3-S4

2020

Link zum Volltext

Verfügbarkeit prüfen

Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanoma

Annals of oncology, 2016-10, Vol.27, p.vi117-vi117

2016

Link zum Volltext

Verfügbarkeit prüfen

1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors

Annals of oncology, 2020-09, Vol.31, p.S981-S982

2020

Link zum Volltext

Verfügbarkeit prüfen

FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab

Clinical nuclear medicine, 2020-04, Vol.45 (4), p.267

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

Annals of oncology, 2008-01, Vol.19 (1), p.86-91

2008

Link zum Volltext

Verfügbarkeit prüfen

Novel trial designs for patients with gastrointestinal stromal tumor

ESMO open, 2024-01, Vol.9 (1), p.102218-102218, Article 102218

2024

Link zum Volltext

Verfügbarkeit prüfen

Sarcoma Immunotherapy: Past Approaches and Future Directions

Sarcoma, 2014, Vol.2014 (2014), p.391967-13

2014

Link zum Volltext

Verfügbarkeit prüfen

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.120-120

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Annals of oncology, 2010-04, Vol.21 (4), p.884-894

2010

Link zum Volltext

Verfügbarkeit prüfen

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Annals of oncology, 2012-09, Vol.23, p.ix319

2012

Link zum Volltext

Verfügbarkeit prüfen

Measuring tumor response and shape change on CT: esophageal cancer as a paradigm

Annals of oncology, 2006-06, Vol.17 (6), p.1018-1023

2006

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

Sarcoma, 2015-01, Vol.2015, p.259817-1

2015

Link zum Volltext

Verfügbarkeit prüfen

1069

International journal of radiation oncology, biology, physics, 2006-11, Vol.66 (3), p.S169

2006

Link zum Volltext

Verfügbarkeit prüfen

1069: A Randomized Phase II Trial Comparing Two Paclitaxel (P))-Cisplatin (C) Containing Chemoradiation (CRT) Regimens as Adjuvant Therapy in Resected Gastric Cancer (RTOG 0114

International journal of radiation oncology, biology, physics, 2006, Vol.66 (3), p.S169-S169

2006

Link zum Volltext

Verfügbarkeit prüfen

Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers

Annals of oncology, 2003-01, Vol.14 (suppl-2), p.ii17-ii23

2003

Link zum Volltext

Verfügbarkeit prüfen

217 Srp20, the first transcriptionally up-regulated gene by flavopiridol (flavo), is a pre-mRNA splicing factor that induces apoptosis in human colon cancer cells

European journal of cancer supplements, 2004-09, Vol.2 (8), p.67-67

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(52)
Bücher
(1)

Sprache

Englisch
(53)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Humans
(25)
Female
(16)
Male
(15)
Oncology
(12)
Adult
(11)
Aged
(9)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Middle Aged
(8)
Treatment Outcome
(8)
Radiology, Nuclear Medicine & Medical Imaging
(7)
Antineoplastic Agents
(6)
Pharmacology. Drug Treatments
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Infant
(5)
Tumors
(5)
Aged, 80 And Over
(4)
Gastroenterology. Liver. Pancreas. Abdomen
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

PP 66 Utility of VEGF and IL-6 as biomarkers for response to PTC299, a novel antiangiogenic

9330 POSTER Memorial Sloan-Kettering Cancer Center (MSKCC) Single-Institutional Vulvovaginal Mucosal Melanoma (WMM) Experience From 1995-2010

1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma

1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma

Development of cell-cycle inhibitors for cancer therapy

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanoma

1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors

FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

Novel trial designs for patients with gastrointestinal stromal tumor

Sarcoma Immunotherapy: Past Approaches and Future Directions

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Measuring tumor response and shape change on CT: esophageal cancer as a paradigm

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”

1069

1069: A Randomized Phase II Trial Comparing Two Paclitaxel (P))-Cisplatin (C) Containing Chemoradiation (CRT) Regimens as Adjuvant Therapy in Resected Gastric Cancer (RTOG 0114

Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers

217 Srp20, the first transcriptionally up-regulated gene by flavopiridol (flavo), is a pre-mRNA splicing factor that induces apoptosis in human colon cancer cells

Suchergebnisse filtern